Latest Pharma Insights
Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement
The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in...
Medtech Insight - October 2, 2023
The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in...
Medtech Insight - October 2, 2023
Holocare Hopes To Bring New Dimensions To Surgical Planning
The company has developed a method to convert DICOM images into 3D holograms that can be projected onto VR headsets...
Medtech Insight - October 2, 2023
The company has developed a method to convert DICOM images into 3D holograms that can be projected onto VR headsets...
Medtech Insight - October 2, 2023
Why Are UK CBD Brands Pivoting Into Functional Mushroom Supplements?
Ongoing regulatory issues and restrictive marketing rules are prompting CBD brands to pivot to functional mushrooms, the market for which...
HBW Insight - October 2, 2023
Ongoing regulatory issues and restrictive marketing rules are prompting CBD brands to pivot to functional mushrooms, the market for which...
HBW Insight - October 2, 2023
The Separation Of Sandoz, A Story Years In The Making
Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On...
Generics Bulletin - October 2, 2023
Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On...
Generics Bulletin - October 2, 2023
Muted APPLAUSE For Novartis In IgAN
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
Scrip - October 2, 2023
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
Scrip - October 2, 2023
UK Govt Under Fire From Pharma Industry Over Statutory Pricing Scheme Changes
The UK’s pharmaceutical industry association, the ABPI, claims that “fundamental failures” in the government’s consultation and impact assessment for proposed...
Pink Sheet - October 2, 2023
The UK’s pharmaceutical industry association, the ABPI, claims that “fundamental failures” in the government’s consultation and impact assessment for proposed...
Pink Sheet - October 2, 2023
Stock Watch: The Rise Of Biotech Platforms
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely...
Scrip - October 2, 2023
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely...
Scrip - October 2, 2023
Opportunities In Fertility: Recognizing Gaps In The Market
Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be...
In Vivo - October 2, 2023
Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be...
In Vivo - October 2, 2023
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out...
In Vivo - October 2, 2023
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out...
In Vivo - October 2, 2023
Biogen Gets First US Tocilizumab Biosimilar
Biogen has celebrated the approval by the US FDA of its Bio-Thera-partnered Tofidence biosimilar rival to Actemra. The firm said...
Generics Bulletin - October 2, 2023
Biogen has celebrated the approval by the US FDA of its Bio-Thera-partnered Tofidence biosimilar rival to Actemra. The firm said...
Generics Bulletin - October 2, 2023
Fresenius And Formycon File Ustekinumab In Europe
Fresenius Kabi and Formycon have seen their filing for an ustekinumab biosimilar rival to Stelara accepted for review by the...
Generics Bulletin - October 2, 2023
Fresenius Kabi and Formycon have seen their filing for an ustekinumab biosimilar rival to Stelara accepted for review by the...
Generics Bulletin - October 2, 2023
EU Regulatory Roundup, September 2023: Dismantling Regulatory Barriers To Medtech Innovation
The call for more to be done about the EU’s regulatory hurdles to innovation, as well as for improvements to...
Medtech Insight - October 2, 2023
The call for more to be done about the EU’s regulatory hurdles to innovation, as well as for improvements to...
Medtech Insight - October 2, 2023
Haleon Helps Pharmacists #ListentoPain As Social Stigma And Isolation Increases
Haleon finds in its latest global “Pain Index” that people are becoming less tolerant and more judgmental. To help remedy...
HBW Insight - October 2, 2023
Haleon finds in its latest global “Pain Index” that people are becoming less tolerant and more judgmental. To help remedy...
HBW Insight - October 2, 2023
Pneumagen Plots Entry Into COPD Space With Neumifil
With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt...
Scrip - October 2, 2023
With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt...
Scrip - October 2, 2023
Life Sciences Scaling Adoption Of New Metaverse, AI Tools
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive...
Scrip - October 2, 2023
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive...
Scrip - October 2, 2023
Muted APPLAUSE For Novartis In IgAN
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
Scrip - October 2, 2023
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
Scrip - October 2, 2023
Stock Watch: The Rise Of Biotech Platforms
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely...
Scrip - October 2, 2023
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely...
Scrip - October 2, 2023
Pneumagen Plots Entry Into COPD Space With Neumifil
With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt...
Scrip - October 2, 2023
With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt...
Scrip - October 2, 2023
Life Sciences Scaling Adoption Of New Metaverse, AI Tools
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive...
Scrip - October 2, 2023
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive...
Scrip - October 2, 2023
UK Govt Under Fire From Pharma Industry Over Statutory Pricing Scheme Changes
The UK’s pharmaceutical industry association, the ABPI, claims that “fundamental failures” in the government’s consultation and impact assessment for proposed...
Pink Sheet - October 2, 2023
The UK’s pharmaceutical industry association, the ABPI, claims that “fundamental failures” in the government’s consultation and impact assessment for proposed...
Pink Sheet - October 2, 2023
Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement
The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in...
Medtech Insight - October 2, 2023
The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in...
Medtech Insight - October 2, 2023
Holocare Hopes To Bring New Dimensions To Surgical Planning
The company has developed a method to convert DICOM images into 3D holograms that can be projected onto VR headsets...
Medtech Insight - October 2, 2023
The company has developed a method to convert DICOM images into 3D holograms that can be projected onto VR headsets...
Medtech Insight - October 2, 2023
EU Regulatory Roundup, September 2023: Dismantling Regulatory Barriers To Medtech Innovation
The call for more to be done about the EU’s regulatory hurdles to innovation, as well as for improvements to...
Medtech Insight - October 2, 2023
The call for more to be done about the EU’s regulatory hurdles to innovation, as well as for improvements to...
Medtech Insight - October 2, 2023
Why Are UK CBD Brands Pivoting Into Functional Mushroom Supplements?
Ongoing regulatory issues and restrictive marketing rules are prompting CBD brands to pivot to functional mushrooms, the market for which...
HBW Insight - October 2, 2023
Ongoing regulatory issues and restrictive marketing rules are prompting CBD brands to pivot to functional mushrooms, the market for which...
HBW Insight - October 2, 2023
Haleon Helps Pharmacists #ListentoPain As Social Stigma And Isolation Increases
Haleon finds in its latest global “Pain Index” that people are becoming less tolerant and more judgmental. To help remedy...
HBW Insight - October 2, 2023
Haleon finds in its latest global “Pain Index” that people are becoming less tolerant and more judgmental. To help remedy...
HBW Insight - October 2, 2023
The Separation Of Sandoz, A Story Years In The Making
Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On...
Generics Bulletin - October 2, 2023
Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On...
Generics Bulletin - October 2, 2023
Biogen Gets First US Tocilizumab Biosimilar
Biogen has celebrated the approval by the US FDA of its Bio-Thera-partnered Tofidence biosimilar rival to Actemra. The firm said...
Generics Bulletin - October 2, 2023
Biogen has celebrated the approval by the US FDA of its Bio-Thera-partnered Tofidence biosimilar rival to Actemra. The firm said...
Generics Bulletin - October 2, 2023
Fresenius And Formycon File Ustekinumab In Europe
Fresenius Kabi and Formycon have seen their filing for an ustekinumab biosimilar rival to Stelara accepted for review by the...
Generics Bulletin - October 2, 2023
Fresenius Kabi and Formycon have seen their filing for an ustekinumab biosimilar rival to Stelara accepted for review by the...
Generics Bulletin - October 2, 2023
Opportunities In Fertility: Recognizing Gaps In The Market
Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be...
In Vivo - October 2, 2023
Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be...
In Vivo - October 2, 2023
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out...
In Vivo - October 2, 2023
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out...
In Vivo - October 2, 2023
